SARDOCOR CORP.

• Medera Inc. has completed Cohort A (low-dose) and initiated dosing in Cohort B (high-dose) of the MUSIC-HFpEF trial, evaluating SRD-002 for heart failure with preserved ejection fraction (HFpEF). • Early data from Cohort A shows promising efficacy in cardiovascular performance at six months, with no unexpected toxicities observed, supporting the progression to the higher dose cohort. • SRD-002, a gene therapy delivering the SERCA2a gene, aims to address the unmet need for disease-modifying therapeutics in HFpEF, which affects nearly half of all heart failure patients. • Enrollment in Cohort B is expected to complete in Q1 2025, with interim data anticipated in the first half of 2025, marking a key milestone in SRD-002's clinical development.

Medera's SRD-002 Gene Therapy Advances in Phase 1/2a Trial for HFpEF